Clinical trials: Lipemia
Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.
- Trial name
- NCT00309738
- Testing
- pitavastatin, simvastatin
- Where
- 35 sites in Denmark, Netherlands and 2 more
- Volunteers
- 355 people
- Sponsor
- Kowa Research Europe
Vascular Diseases, Hypercholesterolemia
The Effect of Plant Sterols on Vascular Function
The main aim of the study is to investigate, in humans, the effect of plant sterols on vascular function by measuring flow-mediated dilation (FMD).
- Trial name
- NCT01803178
- Testing
- Plant Sterols
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Hypercholesterolemia, Dyslipidemia
Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- LANCE (NCT01420549)
- Testing
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Hypercholesteremia
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
- Trial name
- NCT00225589
- Testing
- Rosuvastatin calcium
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 840 people
- Sponsor
- AstraZeneca
Hypercholesterolaemia
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in…
- Trial name
- NCT07610278
- Testing
- QCZ484, Inclisiran
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolaemia
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
To evaluate the effect of atorvastatin 80 mg, versus placebo, given for 12 months on carotid intima-media thickness in postmenopausal women with moderate hypercholesterolemia.
- Trial name
- NCT00163163
- Testing
- Echographic measurements, Blood samples
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 400 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT)…
- Trial name
- NCT02289963
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 27 sites in South Korea, Taiwan
- Volunteers
- 199 people
- Sponsor
- Sanofi
Hypertension, Hyperlipidemia
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT02899455
- Testing
- HGP0904, HGP0608, HGP0816
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic properties of Telmisartan/S-amlodipine
- Trial name
- CKD-345 DDI (NCT01842230)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, Telmisartan 80mg and S-amlodipine 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemias, High Cholesterol
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Trial name
- ROSE (NCT04753606)
- Testing
- Obicetrapib
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia, Coronary Heart Disease
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
This is a multicenter, randomized, parallel group, placebo controlled study designed to evaluate the efficacy, safety, and tolerability of ezetimibe added to ongoing atorvastatin therapy compared with ongoing atorvastatin…
- Trial name
- NCT00202904
- Testing
- ezetimibe
- Volunteers
- 81 people
- Sponsor
- Organon and Co
Healthy, Hypercholesterolemia
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
The goal of this study is to learn what happens to different doses of enlicitide chloride over time in the body of healthy participants and participants taking statins, a group of medicines used to reduce the levels of high…
- Trial name
- NCT06655311
- Testing
- Enlicitide Chloride
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD risk strata of the NCEP III guidelines to achieve…
- Trial name
- NCT00651014
- Testing
- Ezetimibe
- Volunteers
- 82 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia
Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00776321
- Testing
- Eprotirome
- Where
- Sweden
- Volunteers
- 142 people
- Sponsor
- Karo Bio AB
Hypercholesterolemia
Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet
To determine whether new 80 mg atorvastatin tablets are bioequivalent to 80 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917644
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Coronary Syndrome
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS)…
- Trial name
- V-INCEPTION (NCT04873934)
- Testing
- Inclisiran
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
In this study participants will receive NNC0385-0434. NNC0385-0434 is being developed for the treatment of hypercholesterolemia, a fat metabolism disorder characterized by high levels of cholesterol in the blood.
- Conditions
- Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
- Trial name
- NCT05091073
- Testing
- NNC0385-0434
- Where
- Germany
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia, Familial Hypercholesterolemia
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a…
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia
- Trial name
- NCT00705211
- Testing
- Ezetimibe, Ezetimibe + other lipid-lowering medication(s)
- Volunteers
- 1,794 people
- Sponsor
- Organon and Co
Overweight, Elevated Cholesterol
Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man
This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels…
- Trial name
- Lyzme5 (NCT01634646)
- Testing
- Lyzme5
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Jeff Golini
Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease, Heterozygous Familial Hypercholesterolemia, Hypercholesterolemia
- Trial name
- NCT06112327
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 116 people
- Sponsor
- Verve Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.